Last reviewed · How we verify
Ustekinumab - Half-Standard Dosage
Ustekinumab is a monoclonal antibody that blocks the action of interleukin-12 and interleukin-23, which are proteins involved in inflammation.
Ustekinumab is a monoclonal antibody that blocks the action of interleukin-12 and interleukin-23, which are proteins involved in inflammation. Used for Moderate to severe plaque psoriasis, Moderate to severe Crohn's disease.
At a glance
| Generic name | Ustekinumab - Half-Standard Dosage |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Drug class | IL-12/23 inhibitor |
| Target | p40 subunit of IL-12 and IL-23 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By blocking these proteins, ustekinumab reduces inflammation and slows disease progression in conditions such as psoriasis and Crohn's disease. This is achieved through the inhibition of the JAK-STAT signaling pathway, which is involved in the production of pro-inflammatory cytokines.
Approved indications
- Moderate to severe plaque psoriasis
- Moderate to severe Crohn's disease
Common side effects
- Injection site reactions
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (PHASE2)
- A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |